Clinical trials: Radiotherapy
Cervical Cancer
Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer
This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy.
- Trial name
- NCT02247232
- Testing
- Z-100
- Where
- 7 sites in Japan, Malaysia and 5 more
- Volunteers
- 793 people
- Sponsor
- Zeria Pharmaceutical
Enteritis Caused by Radiation (Disorder)
Pharmacokinetics, Safety, and Tolerability of SYN-020
This is a Phase 1, single-center, open-label, single ascending dose study to assess the PK, safety, and tolerability of SYN-020 delayed release capsules administered orally to healthy adult male and female subjects with a BMI of…
- Trial name
- NCT04815993
- Testing
- SYN-020 delayed release capsule
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Theriva Biologics, Inc.
Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
- Conditions
- Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
- Trial name
- AMPLIFY (NCT06970847)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 22 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Head and Neck Cancer
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
This two-arm study will compare the efficacy and safety of erlotinib (Tarceva) versus placebo in participants with resected head and neck squamous cell cancer who are receiving concurrent chemoradiotherapy or radiotherapy alone.
- Trial name
- NCT00412217
- Testing
- Erlotinib, Standard of care
- Where
- 31 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Hoffmann-La Roche
Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive…
- Trial name
- NCT01906385
- Testing
- Rhenium Liposome Treatment
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cerenome
Breast Lesions, Breast Cyst
Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning
The purposes of this study is to establish normal optical values of breast tissue in the general population. This will allow for establishing normals for breast composition, and is expected to be useful in the classification of…
- Conditions
- Breast Lesions, Breast Cyst, Early-Stage Breast Cancer, Benign Growth, Breast
- Trial name
- NCT00671385
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Spectros Corporation
SBRT, Borderline Resectable Pancreatic Cancer
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline…
- Conditions
- SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT04698915
- Testing
- Drug GC4711
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 177 people
- Sponsor
- Galera Therapeutics, Inc.
Brain Metastases
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After…
- Trial name
- PURSUE (NCT04410367)
- Testing
- 18F fluciclovine
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Blue Earth Diagnostics
Hyperpigmentation, Photodamaged Skin
A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging
This open-label, multi-center clinical trial was conducted to evaluate the dual skincare regimen of vitamin C serum and moisturizing sunscreen SPF 45 to improve facial hyperpigmentation and photodamage after 12 weeks of twice…
- Conditions
- Hyperpigmentation, Photodamaged Skin, Wrinkle, Fine Lines
- Trial name
- NCT05423873
- Testing
- Gentle Cleansing Lotion, Revision Skincare
- Where
- 3 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Head and Neck Cancer, Thoracic Cancer
Evaluation of On-Couch CBCT Image Quality
This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology (HyperSight) in patients receiving…
- Conditions
- Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
- Trial name
- NCT06576908
- Testing
- HyperSight Imaging
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Varian, a Siemens Healthineers Company
Pancreas Cancer
Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
- Trial name
- LAPC (NCT05191940)
- Testing
- Particle-therapy using protons or carbon ions, Blood sampling, Magnetic resonance imaging
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- EBG MedAustron GmbH
Carcinoma, Non-Small-Cell Lung
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in…
- Trial name
- NCT03643484
- Where
- 37 sites in Japan
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Glioblastoma
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as…
- Trial name
- NCT00943826
- Testing
- Bevacizumab, Temozolomide, Radiation therapy
- Where
- 133 sites in United States, Australia and 22 more
- Volunteers
- 921 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
The purpose of this surveillance is to collect more safety and efficacy data in "non-study" patients during concomitant and adjuvant temozolomide therapy.
- Trial name
- NCT00704808
- Testing
- Primary surgical treatment, Radiotherapy, Temozolomide
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON (NCT07197580)
- Testing
- 177Lu-TLX250
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Pain, Back Pain
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the treatment of acute low back pain.
- Conditions
- Pain, Back Pain, Low Back Pain, Back Pain With Radiation
- Trial name
- NCT00986180
- Testing
- NUCYNTA, Oxycodone IR
- Where
- 74 sites in United States
- Volunteers
- 667 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Squamous Cell Carcinoma of the Head and Neck
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than…
- Trial name
- NCT03349710
- Testing
- Nivolumab, Cetuximab, Cisplatin
- Where
- 55 sites in United States, France and 8 more
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Chordoma, Unresectable Malignant Neoplasm
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.
- Trial name
- NCT03647423
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-051
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Metastatic Non-Small Cell Lung Cancer
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases
This is a randomized, Phase II study designed to investigate Nimotuzumab plus whole-brain radiation therapy (WBRT)and to compare it rith WBRT alone in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT00872482
- Testing
- nimotuzumab
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- YM BioSciences